Progesterone (Luteal Support) Global Regulatory Status: What Every Woman Should Know

What "Luteal Support" Means and Why Regulators Care

Luteal support means replacing or supplementing the progesterone your body would normally produce after ovulation. In a natural cycle, the corpus luteum does this job. In an IVF cycle, ovarian stimulation and egg retrieval compromise corpus luteum function, which drops progesterone sharply at exactly the moment a fertilized embryo needs it to implant. Progesterone concentrations below roughly 10 ng/mL in the mid-luteal phase are associated with cycle failure, and the gap between what the corpus luteum can supply and what implantation requires is large enough that untreated IVF cycles have dramatically lower live-birth rates.

Regulators treat luteal-support products as prescription drugs subject to full clinical-trial review, not as supplements, because the doses involved, roughly 90 mg per day of progesterone gel or 100 mg three times daily of the vaginal insert, are pharmacologically active and because the patient population is pregnant or actively trying to conceive.

Why Vaginal Delivery Changed the Field

Oral progesterone is extensively metabolized on the first pass through the liver, leaving bioavailability around 10 percent. Vaginal delivery bypasses hepatic first-pass metabolism almost entirely. The "uterine first-pass effect" concentrates vaginally administered progesterone directly in the endometrium, producing endometrial tissue levels several-fold higher than serum levels would predict. That pharmacokinetic difference is why regulators accepted vaginal, rather than oral, dosing forms as the standard for luteal support trials.

The Female-Specific Pharmacology That Regulators Evaluated

Progesterone's effects are highly estrogen-dependent. The endometrium responds to progesterone only after estrogen has primed progesterone receptors. In a stimulated IVF cycle, estrogen priming is usually excellent, making the endometrium highly responsive. In a natural frozen embryo transfer (FET) cycle or in a perimenopausal woman, estrogen levels vary widely, and the tissue response to any fixed progesterone dose is less predictable. Regulators approved specific dose regimens for specific indications partly because of this sex-specific pharmacological dependency.

FDA Regulatory History: Approvals, Labeling, and Post-Market Requirements

The FDA has approved multiple progesterone formulations for luteal support. Here is the documented history.

Crinone 8% Vaginal Gel

Crinone 8% progesterone vaginal gel (90 mg per applicator) received FDA approval in 1997 for luteal-phase support in infertile women with progesterone deficiency as part of an ART treatment cycle. The NDA holder was originally Columbia Laboratories; the product has since changed hands to Allergan and subsequently to AbbVie. The approval was based on a randomized, multicenter, open-label trial demonstrating non-inferior pregnancy and live-birth rates compared to intramuscular progesterone in oil.

Endometrin 100 mg Vaginal Insert

Endometrin (progesterone vaginal insert, 100 mg) was approved by the FDA in June 2007 for luteal support as part of ART treatment for infertile women. The key trial, a multicenter, open-label, randomized study, compared Endometrin 100 mg twice daily and 100 mg three times daily against intramuscular progesterone 90 mg once daily. Ongoing pregnancy rates were 30 percent (twice-daily arm) and 29 percent (three-times-daily arm) versus 31 percent for IM progesterone, establishing clinical non-inferiority.

Prometrium 100 mg and 200 mg Oral Capsules

Prometrium (micronized progesterone in peanut oil, oral) received FDA approval in 1998 for two indications: prevention of endometrial hyperplasia in postmenopausal women on estrogen, and secondary amenorrhea. Luteal support in ART is an off-label use of Prometrium, though it is used vaginally off-label for this purpose given the pharmacokinetic advantages described above.

Current FDA-Approved Labeling: Key Points for Clinicians and Patients

The FDA-approved prescribing information for vaginal progesterone products contains several labeling points directly relevant to women:

• Indication specificity. The approved indication is luteal support in ART. Use for recurrent pregnancy loss, threatened abortion, or luteal-phase defect in natural cycles is not FDA-labeled, though ASRM practice guidelines discuss these uses in clinical context.
• Duration. The label specifies continuation through the first 10 to 12 weeks of pregnancy. Stopping abruptly before 10 weeks risks luteal withdrawal in cycles where the placenta has not yet fully taken over progesterone synthesis.
• Contraindications. Active thromboembolic disorders, known sensitivity to progesterone or any product component, undiagnosed vaginal bleeding, and known or suspected malignancy of the breast or genital organs are all labeled contraindications.
• Warnings. The label includes warnings about depression (progesterone can worsen depressive symptoms in some women), fluid retention, and jaundice.

European Regulatory Status (EMA and National Agencies)

The European Medicines Agency does not issue a single centralized approval for all progesterone products; some are approved via the centralized procedure and others via national procedures. Utrogestan (micronized progesterone 100 mg and 200 mg capsules, Besins Healthcare) is the most widely used product across EU member states and is approved for luteal support in ART in France, Germany, Belgium, the Netherlands, and most other EU countries. Crinone 8% gel holds marketing authorizations in the UK (under the MHRA post-Brexit), Ireland, and several other European markets.

The EMA's Committee for Medicinal Products for Human Use (CHMP) has evaluated progesterone safety data across multiple applications, and the European public assessment reports consistently note that vaginal micronized progesterone is safe and effective for luteal support when used per the approved dosing regimen. The EU label similarly restricts the approved indication to ART luteal support and endometrial preparation, and carries the same thromboembolic and depression warnings as the US label.

UK (MHRA) Status Post-Brexit

After Brexit, the MHRA assumed sole responsibility for UK marketing authorizations. Crinone and Cyclogest (progesterone pessaries 200 mg and 400 mg, Actavis) both hold current UK marketing authorizations for luteal support. Cyclogest is notable as a product largely specific to the UK market, widely used in NHS fertility clinics, with a safety record extending back to the 1980s.

Canadian and Australian Regulatory Status

Health Canada has approved Crinone 8% gel for luteal support in ART. The product monograph mirrors the FDA label in its primary indication, contraindications, and pregnancy/lactation guidance.

The Therapeutic Goods Administration (TGA) in Australia lists Crinone under the Australian Register of Therapeutic Goods (ARTG) for use in ART cycles, and Utrogestan has partial market presence. Australian clinical practice frequently supplements vaginal progesterone with oral dydrogesterone, a progestogen with its own TGA approval and a distinct evidence base, particularly following the LOTUS trials.

What the Evidence Actually Shows: Key Trials Every Woman Deserves to Know

The Cochrane Review on Luteal Support in IVF

The most comprehensive systematic review on this topic is the Cochrane review by van der Linden et al., which evaluated luteal-phase support for assisted reproduction, concluding that progesterone supplementation significantly increases clinical pregnancy rates and live-birth rates compared to placebo or no treatment. The review analyzed 94 randomized controlled trials and found moderate-quality evidence supporting vaginal progesterone as the standard of care. Critically, the review also found no statistically significant difference in live-birth rate between vaginal and intramuscular progesterone, validating the regulatory decisions that accepted vaginal delivery as the comparator benchmark.

One thing rarely spelled out for patients: the Cochrane reviewers explicitly noted that most trials were conducted in IVF populations with controlled ovarian stimulation, making it harder to generalize findings to natural cycles or to women using frozen embryo transfer with minimal or no gonadotropin priming. This evidence gap is real. If you are doing a natural-cycle FET, your clinician is applying trial data from a somewhat different population.

Route-of-Administration Trials: What They Mean for Your Prescription

Three routes are in active clinical use: vaginal gel, vaginal insert or suppository, and intramuscular (IM) injection. Subcutaneous progesterone (Prolutex in Europe) also has an established evidence base. A large network meta-analysis found no statistically significant difference in live-birth rates across vaginal gel, vaginal insert, and IM progesterone, but patient tolerability differs substantially. IM progesterone causes injection-site reactions, nodules, and significant discomfort in many women; vaginal products cause local discharge and mild irritation but are preferred by most patients in quality-of-life studies.

The PROMISE Trial and Recurrent Pregnancy Loss

The PROMISE trial, a UK-based double-blind randomized controlled trial published in the New England Journal of Medicine, tested vaginal progesterone 400 mg twice daily from positive pregnancy test to 12 weeks gestation in women with unexplained recurrent miscarriage, finding no statistically significant difference in live-birth rates versus placebo (65.8% vs. 63.3%). The PRISM trial subsequently found a signal of benefit in women with three or more prior losses and those with early pregnancy bleeding. Neither trial generated a new FDA approval. Regulatory agencies in Europe and the US have reviewed this data without extending the label, which is why use for recurrent pregnancy loss remains off-label in most jurisdictions.

Pregnancy and Lactation Safety: The Section That Should Be in Every Label Discussion

This section is required reading for any woman who is pregnant, trying to conceive, or breastfeeding.

Pregnancy Category and Human Data

Under the older FDA pregnancy category system, micronized progesterone vaginal is Category B, meaning animal studies showed no fetal harm and adequate well-controlled studies in pregnant women either showed no risk or were not available. Progesterone is a naturally occurring hormone essential for pregnancy maintenance. There is no established teratogenic signal from micronized progesterone at doses used for luteal support.

The PDUFA label update system replaced letter categories with narrative pregnancy and lactation data in 2015. Under the current Pregnancy and Lactation Labeling Rule (PLLR), the FDA-approved labeling states that the available data from postmarketing surveillance do not indicate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes when progesterone is used for luteal support. This is reassuring, but it comes with a caveat: postmarketing surveillance data in reproductive-age women is frequently confounded by the underlying indication (infertility itself carries elevated risk of miscarriage and preterm birth), so it is harder to attribute outcomes to the drug itself.

Contraception Requirement

None. Progesterone vaginal for luteal support is used specifically to support an established or anticipated pregnancy. It is not a contraceptive. In fact, stopping it prematurely may compromise early pregnancy. Do not stop your vaginal progesterone without guidance from your prescribing clinician.

Lactation Transfer

Progesterone is excreted into human breast milk. Published pharmacokinetic data show that relative infant dose from vaginal progesterone gel is low, estimated at under 1 percent of the weight-adjusted maternal dose, but strong controlled studies in breastfeeding women are absent. Most luteal-support use ends by 10 to 12 weeks of gestation, before lactation begins. If a woman is using progesterone postpartum for cycle regulation, HRT, or off-label luteal support in a breastfeeding window, she should discuss the risk-benefit with her provider. The product label advises caution.

Peanut Oil Allergy Warning (Prometrium)

Prometrium oral capsules are formulated in peanut oil. Women with a documented peanut allergy must not take Prometrium. Vaginal gel and insert formulations (Crinone, Endometrin) do not contain peanut oil and are safe alternatives from an allergy standpoint.

Who This Is the Right Drug For, and Who Should Pause

Strong Candidates

• Women undergoing fresh or frozen IVF/ICSI cycles, regardless of age or ovarian reserve status.
• Women with a documented luteal-phase defect confirmed by serial mid-luteal progesterone levels.
• Women in donor-egg recipient cycles, where corpus luteum function is absent by design.
• Perimenopausal women on estrogen-only HRT who have an intact uterus and require progestogen for endometrial protection. Note that this is a different dose and formulation strategy than ART luteal support.

Women Who Should Not Use Vaginal Progesterone or Need Careful Review

• Women with a personal history of venous thromboembolic disease. Progesterone increases VTE risk modestly, and the risk is additive when estrogen is also being used.
• Women with hepatic impairment. Progesterone is hepatically metabolized, and impaired clearance can lead to accumulation.
• Women with a known or suspected estrogen- or progesterone-sensitive malignancy.
• Women with a history of severe depression that worsened with hormonal fluctuations. The neurosteroid metabolite allopregnanolone, produced from progesterone, has complex effects on GABA-A receptors that can worsen mood in sensitive individuals.

Life-Stage Variations in Dosing and Monitoring

Reproductive years (ART cycle). Standard luteal support is Crinone 8% gel 90 mg once daily or Endometrin 100 mg two to three times daily, starting on the day of egg retrieval or embryo transfer and continuing through 10 to 12 weeks gestation.

Perimenopause. Women using estrogen therapy who still have a uterus need cyclic or continuous progestogen. Prometrium 200 mg taken orally for 12 days per cycle (sequential) or 100 mg nightly (continuous) are guideline-supported regimens per The Menopause Society 2023 Hormone Therapy Position Statement. The vaginal route is generally not first-line for HRT-related endometrial protection because systemic levels are lower.

Postmenopause. Use follows the same HRT logic. Vaginal progesterone at standard doses achieves insufficient systemic levels to reliably protect the endometrium in postmenopausal women on moderate-to-high-dose estrogen; oral Prometrium or levonorgestrel-releasing IUD is preferred in most guidelines.

Post-Market Surveillance and Long-Term Safety Data

More than two decades of post-market use have accumulated since Crinone's 1997 approval. FDA Sentinel and voluntary adverse-event reporting (FAERS) have not identified new safety signals beyond those already captured in the label.

A large French cohort study, the FAMHES study, monitored adverse events in women using micronized progesterone versus synthetic progestogens in HRT and found that micronized progesterone carried a lower risk of breast cancer and VTE compared to synthetic progestins, though this was an HRT cohort rather than an ART-luteal-support population. These data have influenced European prescribing preferences and are one reason micronized progesterone is now preferred over medroxyprogesterone acetate in many European HRT guidelines, but the FDA has not updated the label on this basis.

The EMA has conducted periodic safety reviews under its Pharmacovigilance Risk Assessment Committee (PRAC) and has not issued new restrictions or Dear Healthcare Professional communications specific to vaginal progesterone for luteal support. The global regulatory picture is therefore one of sustained approval across all major markets, with the label substantially unchanged since the original approvals.

What the Evidence Gaps Mean for You

Women are right to ask why the label still says so little about use beyond 12 weeks, or about natural-cycle FET, or about the optimal dose for diminished ovarian reserve cycles. These gaps exist because:

1. Fertility trials are expensive and hard to blind (IM progesterone is visually distinct from gel).
2. Pregnancy endpoints require long follow-up to live birth, slowing trial completion.
3. Regulators approved an effective product and had little commercial or regulatory pressure to fund post-approval trials in subpopulations.

ASRM's 2023 committee opinion on progesterone supplementation explicitly notes that the evidence base for natural-cycle FET luteal support is limited and that current practice relies heavily on extrapolation. If your doctor prescribes progesterone for a natural-cycle FET or unexplained recurrent loss, they are acting within clinical consensus but outside the FDA label. That is common in reproductive medicine and not inherently unsafe. You deserve to know the distinction.

PCOS, Endometriosis, and Other Female-Specific Conditions

PCOS. Women with PCOS who undergo ovarian stimulation often have high estrogen levels and a different hormonal environment than women with normal ovarian reserve. Progesterone levels can appear adequate in stimulated PCOS cycles, but some data suggest endometrial progesterone receptor expression is altered in PCOS, potentially requiring higher vaginal doses. No FDA label update reflects this; it remains an area of active research.

Endometriosis. Progesterone resistance is well documented in endometriosis-affected endometrium. Studies show reduced progesterone receptor B expression in eutopic and ectopic endometrium from women with endometriosis, which may blunt the expected luteal response. Women with endometriosis undergoing IVF may need supplemental luteal support beyond standard protocols, though no specific dosing adjustment is FDA-labeled.

Recurrent pregnancy loss. As described in the PROMISE and PRISM trial sections above, the FDA and EMA have reviewed this indication and declined to extend the label. Off-label use is common; the evidence is mixed.